The present invention relates to a process for the synthesis of dasatinib and to intermediates useful for its preparation. Dasatinib belongs to a new class of targeted antitumoral drugs, the inhibitors of the tumoral growth; in particular it is an inhibitor of the tyrosine-kinase activity of BRC-ABL and further four oncogenic kinases which is mainly used in the treatment of chronic myelogenous leukemia (CML).
Dasatinib monohydrate is a pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
Dasatinib is a selective tyrosine kinase receptor inhibitor that is used in the therapy of chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. Dasatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent acute liver injury.A hydrate that is the monohydrate of dasatinib. It is used for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN)
